

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound consisting of the formula X_1 -His-Lys-X-Lys- X_2 wherein

X is any amino acid,

X_1 is the segment His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or an N-terminal truncation fragment thereof containing at least one amino acid, and

X_2 is

(i) zero amino acids, or

(ii) the segment Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:2), or a C-terminal truncation fragment thereof containing at least one amino acid,

and wherein said compound optionally comprises an amino-terminal protecting group and optionally comprises a carboxy-terminal protecting group.

2. (Previously presented) The composition of claim 1 wherein

X_1 is from one to six amino acids in length, and

X_2 is from zero to six amino acids in length.

3. (Previously presented) The composition of claim 1 wherein X is selected from the group consisting of Ala, Leu, Ile, Val, Pro, Phe, Trp, Met, Ser, Thr, Tyr, Asn, Gln, Cys, and Gly.

4. (Previously presented) The composition of claim 3 wherein X is Asn, Phe or His.

5. Cancelled

6. Cancelled

7. Cancelled

8. (Previously presented) The composition of claim 1 wherein the compound has the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5).

9. (Previously presented) The composition of claim 1 wherein the compound has the amino acid sequence Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His (SEQ ID NO:7).

10. Cancelled

11. Cancelled

12. Cancelled

13. Cancelled

14. Cancelled

15. Cancelled

16. (Currently Amended) A method of inhibiting angiogenesis comprising administering to a mammal ~~an~~ a pharmaceutically effective amount of a pharmaceutical

composition comprising a pharmaceutically acceptable carrier and a compound of the formula X_1 -His-Lys-X-Lys- X_2 wherein

X is any amino acid,

X_1 is from zero to twelve amino acids, and

X_2 is from zero to twelve amino acids,

and wherein said compound optionally comprises an amino-terminal protecting group and optionally comprises a carboxy-terminal protecting group.

17. Cancelled

18. Cancelled

19. (Currently Amended) A method of inhibiting angiogenesis comprising administering to a mammal ~~an~~ a pharmaceutically effective amount of a two-chain high molecular weight kininogen.

20. Cancelled

21. Cancelled

22. (Currently Amended) A method of inhibiting angiogenesis comprising administering to a mammal ~~an~~ a pharmaceutically effective amount of a single-chain high molecular weight kininogen.

23. Cancelled

24. Cancelled

25. Cancelled

26. Cancelled

27. Cancelled

28. Cancelled

29. Cancelled

30. (Currently Amended) A compound consisting of the formula X_1 -His-Lys-X-Lys- X_2 wherein

X is any amino acid,

X_1 is the segment His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or an N-terminal truncation fragment thereof containing at least one amino acid, and

X_2 is

(i) zero amino acids, or

(ii) the segment Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:2), or a C-terminal truncation fragment thereof containing at least one amino acid, and wherein said compound optionally comprises an amino-terminal protecting group and optionally comprises a carboxy-terminal protecting group.

31. (Previously presented) The compound of claim 30 wherein X is Asn, Phe or His.

32. (Previously presented) The compound of claim 30 having at least about 30% amino acid sequence homology to the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-

Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val
(SEQ ID NO:5).

33. (Previously presented) The compound of claim 30 having the amino acid sequence Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His (SEQ ID NO:7).

34. (Currently Amended) A compound consisting essentially of the amino acid sequence Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn (SEQ ID NO:8).

35. (Currently Amended) A compound consisting essentially of the amino acid sequence His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:9).

36. (Previously presented) The method of claim 16, wherein
X₁ is from zero to six amino acids, and
X₂ is from zero to six amino acids.

37. (Previously presented) The method of claim 16, wherein X is selected from the group consisting of Ala, Leu, Ile, Val, Pro, Phe, Trp, Met, Ser, Thr, Tyr, Asn, Gln, Cys and Gly.

38. (Previously presented) The method of claim 37 wherein X is Asn, Phe, or His.

39. (Previously presented) The method of claim 16, wherein
X₁ is

(i) zero amino acids, or
(ii) the segment His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly
(SEQ ID NO:1), or an N-terminal truncation fragment thereof containing at least one amino acid,
and

X₂ is

(i) zero amino acids, or
(ii) the segment Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val
(SEQ. ID NO:2), or a C-terminal truncation fragment thereof containing at least one amino acid.

40. (Previously presented) The method of claim 39 wherein X is Asn, Phe or His.

41. (Previously presented) The method of claim 16, wherein the compound has at least 30% amino acid sequence homology to the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5).

42. (Previously presented) The method of claim 16, wherein the compound has the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5).

43. (Previously presented) The method of claim 16, wherein the compound has the amino acid sequence Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His (SEQ ID NO:7).

44. (Previously presented) The method of claim 16, wherein
X₁ is

(i) zero amino acids, or

(ii) the segment Gly-His-Lys-His-Lys-His-Gly-His-Gly-His-Lys (SEQ ID NO:3) or an N-terminal truncation fragment thereof containing at least one amino acid, and

X₂ is

(i) zero amino acids, or

(ii) the segment Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:4) or a C-terminal truncation fragment thereof containing at least one amino acid.

45. (Previously presented) The method of claim 44 wherein X is Asn, Phe, or His.

46. (Previously presented) The method of claim 44, wherein the compound has at least 30% amino acid sequence homology to the amino acid sequence Gly-His-Lys-His-Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:6).

47. (Previously presented) The method of claim 44, wherein the compound has the amino acid sequence Gly-His-Lys-His-Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:6).

48. (Previously presented) The method of claim 44, wherein the compound has the amino acid sequence Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn (SEQ ID NO:8).

49. (Previously presented) The method of claim 44, wherein the compound has the amino acid sequence His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:9).